A Answers (1)
There are several new treatments in the pipeline for autism spectrum disorder. Curemark, LLC recently released positive results from a phase 3 clinical trial of their compound, Luminenz, that is focused on treating symptoms of hyperactivity in Autism. Seaside Therapeutics is also studying Arbaclofen, a GABA agonist, for social withdrawal in autism and preliminary results may be available in the next year. The field has also been focused on developing targeted therapeutics for single gene causes of autism, such as Fragile X syndrome and Rett syndrome, and several medications are being actively studied. In Fragile X syndrome alone, Novartis and Roche Pharmaceuticals are conducting clinical trials of different glutamate antagonists, in addition to Seaside’s Arbaclofen.Helpful? 1 person found this helpful.